Literature summary for 3.5.1.99 extracted from

Giacovazzo, G.; Bisogno, T.; Piscitelli, F.; Verde, R.; Oddi, S.; Maccarrone, M.; Coccurello, R.
Different routes to inhibit fatty acid amide hydrolase do all roads lead to the same place? (2019), Int. J. Mol. Sci., 20, E4503 .

Search for more literature for 3.5.1.99

Application

Application	Comment	Organism
medicine	there is evidence indicating that enhancing the endocannabinoid (eCB) tone has therapeutic potential in several brain disorders. The inhibition of endocannabinoid degradation by fatty acid amide hydrolase blockade, is the best-known option to increase N-acyl-ethanolamines-mediated signaling. By showing the efficacy of intranasal FAAH inhibition, evidence is provided that nose-to-brain delivery is a suitable alternative to enhance brain endocannabinoid tone for the treatment of neurodegenerative disorders and improve patients' compliance	Mus musculus

Inhibitors

Inhibitors	Comment	Organism	Structure
PF-04457845	potently inhibits the enzyme regardless the route selected	Mus musculus
URB597	less effective inhibitor in the brain after oral administration while it reaches similar effects by intranasal (i.n.) and intraperitoneal routes. Intranasal URB597 delivery always increased N-acyl-ethanolamine levels in brain areas, whereas a parallel increase is not observed in the liver. By showing the efficacy of intranasal FAAH inhibition, evidence is provided that nose-to-brain delivery is a suitable alternative to enhance brain endocannabinoid tone for the treatment of neurodegenerative disorders and improve compliance of the patients	Mus musculus

Organism

Organism	UniProt	Comment	Textmining
Mus musculus	O08914	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
brain	-	Mus musculus	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
N-arachidonoylethanolamine + H2O	-	Mus musculus	arachidonic acid + ethanolamine	-	?

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)